Health-care shares were generally flat in
) shares were about 3% higher pre-market after the biotechnology
company said an interim analysis of data from its Phase 3 clinical
trial on Kyprolis to treat patients with relapsed multiple myeloma
met the primary endpoint of progression-free survival. AMGN is
trading near the upper end of the 52-week range between $103.31 and
) reported Q2 sales and earnings that missed analysts' estimates.
The provider of point-of-care diagnostics and services said
non-GAAP adjusted income fell to $0.42 per diluted share from $0.64
the year earlier, missing the $0.58 average estimate from analysts
polled by Capital IQ. Sales slipped to $739.9 million from $764.0
million, short of the $748 million consensus.
Symmetry Medical (
) reported fiscal Q2 earnings that were ahead of analysts'
expectations. The provider of medical device solutions, including
surgical instruments, orthopedic implants, and sterilization cases
and trays said adjusted non-GAAP earnings from continuing
operations in the quarter ended June 28 rose 70% to $0.17,
exceeding the $0.12 average estimate from analysts polled by
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.